AMDL, Inc. Announces Strategic Realignment
October 14 2008 - 9:30AM
PR Newswire (US)
Company restructures business into three distinct divisions that
include in vitro diagnostics, cancer therapeutics and China-based
integrated pharmaceuticals TUSTIN, Calif., Oct. 14
/PRNewswire-FirstCall/ -- (http://www.amdl.com/) AMDL, Inc.
(AMEX:ADL), a vertically integrated pharmaceutical company with
major operations in China and the US, today announced it has
restructured its business into three distinct divisions to better
reflect the Company's operational focus on becoming a world-class,
diversified pharmaceutical company. The new divisions include an In
Vitro Diagnostics (IVD) division specifically focused on
accelerating AMDL's market launch for the AMDL-ELISA DR-70(R) (FDP)
cancer test; a Cancer Therapeutics division specifically focused on
accelerating research for its Combination Immunogene Therapy (CIT)
technology; and a China-based Integrated Pharmaceuticals division
focused on the continued manufacturing, sales and distribution of
AMDL's broad range of generic, specialty and branded pharmaceutical
products. AMDL will continue to execute its 2008 business plan with
a focus on achieving its stated financial target of a 100% increase
in sales over 2007. Additionally, under this new operational
structure, AMDL will aggressively work to: -- Establish the IVD
division for DR-70 with a structural platform for funding the
division through a potential joint-venture partnership(s) or
selling the division as a stand-alone business; -- Establish the
Cancer Therapeutics division with a structural platform for funding
the division through a potential joint-venture partnership(s) or
selling the division as a stand-alone business; -- Continue
accelerating the manufacturing, sales & marketing of AMDL's
diverse China-based pharmaceutical product portfolio through the
Integrated Pharmaceuticals division; and, -- Leverage AMDL's
current assets and resources to drive future growth. "Segmenting
AMDL's operations into these three distinct divisions provides us
with greater market focus, increased flexibility across our diverse
product portfolio, and a solid platform to successfully execute
AMDL's key business goals," commented Mr. Gary Dreher, President
and CEO of AMDL. "We've achieved significant growth in sales and
gross profits over the past 18 months and believe this refinement
will strengthen AMDL's long-term growth position as a leading
developer, manufacturer and supplier of high-quality diagnostic and
pharmaceutical products." For additional information on AMDL and
its diversified product portfolio visit the Company's website at
http://www.amdl.com/ or contact AMDL Investor Relations at
206.310.5323. About AMDL: Headquartered in Tustin, CA with
operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc.,
along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a
vertically integrated bio-pharmaceutical company devoted to the
research, development, manufacturing, and marketing of diagnostic,
pharmaceutical, nutritional supplement, and cosmetic products. The
company employs approximately 320 people in the U.S. and China. The
Company has an additional 4 pharmaceutical and diagnostic products
under review by various regulatory authorities. Forward Looking
Statements: Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995: The statements contained in this
document include certain predictions and projections that may be
considered forward-looking statements under securities law. These
statements involve a number of important risks and uncertainties
that could cause actual results to differ materially including, but
not limited to, the performance of joint venture partners, as well
as other economic, competitive and technological factors involving
the Company's operations, markets, services, products, and prices.
With respect to AMDL Inc., except for the historical information
contained herein, the matters discussed in this document are
forward-looking statements involving risks and uncertainties that
could cause actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties
related to the Company's access to additional capital, competition
and dependence on key management. Kristine Szarkowitz
Director-Investor Relations (Tel :) 206.310.5323 DATASOURCE: AMDL,
Inc. CONTACT: Kristine Szarkowitz, Director-Investor Relations of
AMDL, Inc., +1-206-310-5323, Web site: http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From May 2024 to Jun 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2023 to Jun 2024